No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey

Ann Hematol. 2022 May;101(5):1115-1117. doi: 10.1007/s00277-022-04774-2. Epub 2022 Feb 4.

Authors

Eriko Hamada¹, Kazuya Sakai¹, Shinya Yamada¹, Masayuki Kubo¹, Masaki Hayakawa¹, Masanori Matsumoto²

Affiliations

¹ Department of Blood Transfusion Medicine, Nara Medical University, Shijyo-cho 840, Kashihara, Nara, 634-8522, Japan.
² Department of Blood Transfusion Medicine, Nara Medical University, Shijyo-cho 840, Kashihara, Nara, 634-8522, Japan. mmatsumo@naramed-u.ac.jp.

No abstract available

Publication types

Letter

MeSH terms

ADAMTS13 Protein
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Japan / epidemiology
Purpura, Thrombotic Thrombocytopenic* / epidemiology
Purpura, Thrombotic Thrombocytopenic* / genetics
RNA, Messenger
Registries
mRNA Vaccines

Substances

COVID-19 Vaccines
RNA, Messenger
mRNA Vaccines
ADAMTS13 Protein